Enno Klussmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Enno Klussmann has a total of 356 co-authors. Here are the top co-authors by number of shared publications:
Kerstin Zühlke
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
16 shared publicationsJenny Eichhorst
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L.).
6 shared publicationsJens Peter von Kries
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)
6 shared publicationsBurkhard Wiesner
LeibnizForschingsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany
5 shared publications- Gunnar Dittmar
Luxembourg Institute of Health
5 shared publications Adeeb Eldahshan
Max Delbrück Center for Molecular Medicine Berlin (MDC), Berlin, Germany
4 shared publications
Latest Publications
- 1 October 2026
- Published by American Physiological Society in Physiological Reviews
- Vol. 106 (4) , 2189-2266
AKAP signaling: physiological and pathophysiological roles and opportunities for novel therapeutic concepts
A-kinase anchoring proteins (AKAPs) received their name based on their ability to bind protein kinase A (PKA). Now, AKAPs have grown to a diverse family of more than 50 proteins, coordinating molecules far beyond PKA and the PKA signaling pathway. AKAPs are scaffolding proteins spanning in size between 15 and several hundred kilodaltons and can directly engage in protein interactions with other signaling proteins, their upstream regulators, and their downstream effectors. AKAPs possess unique targeting domains directing them to defined cellular compartments to coordinate cellular signaling spatially and temporally. A few AKAPs possess their own catalytic activity. AKAPs are crucial in directing cAMP signaling locally and in mediating cross talk with other second messenger systems. This review introduces individual AKAPs and their physiological functions in their respective cellular compartments and illustrates how they organize local signal transduction. The crucial role of AKAPs in coordinating cAMP responses to extracellular cues and how they facilitate specific responses to each stimulus will be exemplified. Dysregulation of AKAPs is associated with or causes disease. We will examine the pathophysiological roles of AKAPs in inherited and noninherited noncommunicable diseases, such as cardiovascular diseases and cancer. Due to the lack of understanding of molecular mechanisms underlying most of these diseases, the available therapeutic approaches often only slow progression and cause side effects. This review will discuss the unique opportunities AKAPs provide to address the medical need for novel therapeutic concepts. Finally, gaps in our knowledge about AKAPs will be outlined, and future directions in AKAP research will be suggested.
- 1 October 2026
- Published by American Physiological Society in Physiological Reviews
- Vol. 106 (4) , 2189-2266
AKAP signaling: physiological and pathophysiological roles and opportunities for novel therapeutic concepts
A-kinase anchoring proteins (AKAPs) received their name based on their ability to bind protein kinase A (PKA). Now, AKAPs have grown to a diverse family of more than 50 proteins, coordinating molecules far beyond PKA and the PKA signaling pathway. AKAPs are scaffolding proteins spanning in size between 15 and several hundred kilodaltons and can directly engage in protein interactions with other signaling proteins, their upstream regulators, and their downstream effectors. AKAPs possess unique targeting domains directing them to defined cellular compartments to coordinate cellular signaling spatially and temporally. A few AKAPs possess their own catalytic activity. AKAPs are crucial in directing cAMP signaling locally and in mediating cross talk with other second messenger systems. This review introduces individual AKAPs and their physiological functions in their respective cellular compartments and illustrates how they organize local signal transduction. The crucial role of AKAPs in coordinating cAMP responses to extracellular cues and how they facilitate specific responses to each stimulus will be exemplified. Dysregulation of AKAPs is associated with or causes disease. We will examine the pathophysiological roles of AKAPs in inherited and noninherited noncommunicable diseases, such as cardiovascular diseases and cancer. Due to the lack of understanding of molecular mechanisms underlying most of these diseases, the available therapeutic approaches often only slow progression and cause side effects. This review will discuss the unique opportunities AKAPs provide to address the medical need for novel therapeutic concepts. Finally, gaps in our knowledge about AKAPs will be outlined, and future directions in AKAP research will be suggested.
- Open Access
- 24 September 2026
- Published by Elsevier in Kidney International
Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance
- 24 September 2026
- Published by Elsevier in Kidney International
Open AccessImpact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance
- Open Access
Gβγ dually regulates the M-current via increased channel surface expression and PIP2 sensitivity
The M-current, generated by voltage gated K V 7.2/7.3 channels, sets the threshold for neuronal action potential and acts as a key brake on repetitive firing. The M-current is tightly regulated by signaling molecules, such as calmodulin and phosphatidylinositol-4,5-bisphosphate (PIP 2 ). Here, we show that coexpression of the ubiquitous subunit dimer of heterotrimeric G-proteins, Gβγ, with K V 7.2/7.3 in Xenopus laevis oocytes doubles maximal M-current. This regulation requires free, prenylated, membrane–associated Gβγ and operates via two distinct mechanisms: 1) increasing plasma membrane (PM) channel density and 2) stabilizing K V 7.2/7.3-PIP₂ coupling. Conversely, Gβγ scavengers reduce basal K V 7.2/7.3 current and weaken PIP 2 coupling. Proximity ligation assays confirm colocalization of Gβγ and K V 7.2/7.3 in the PM. Peptide array and AlphaFold modeling identify putative interaction sites on the channel’s cytoplasmic domain. Finally, the disease–causing Gβ 1 variant I80N abolished Gβγ–induced M-current potentiation. Together, these findings establish Gβγ as a significant physiological regulator and potential site of vulnerability in neuronal M-current function.
Open AccessGβγ dually regulates the M-current via increased channel surface expression and PIP2 sensitivity
The M-current, generated by voltage gated K V 7.2/7.3 channels, sets the threshold for neuronal action potential and acts as a key brake on repetitive firing. The M-current is tightly regulated by signaling molecules, such as calmodulin and phosphatidylinositol-4,5-bisphosphate (PIP 2 ). Here, we show that coexpression of the ubiquitous subunit dimer of heterotrimeric G-proteins, Gβγ, with K V 7.2/7.3 in Xenopus laevis oocytes doubles maximal M-current. This regulation requires free, prenylated, membrane–associated Gβγ and operates via two distinct mechanisms: 1) increasing plasma membrane (PM) channel density and 2) stabilizing K V 7.2/7.3-PIP₂ coupling. Conversely, Gβγ scavengers reduce basal K V 7.2/7.3 current and weaken PIP 2 coupling. Proximity ligation assays confirm colocalization of Gβγ and K V 7.2/7.3 in the PM. Peptide array and AlphaFold modeling identify putative interaction sites on the channel’s cytoplasmic domain. Finally, the disease–causing Gβ 1 variant I80N abolished Gβγ–induced M-current potentiation. Together, these findings establish Gβγ as a significant physiological regulator and potential site of vulnerability in neuronal M-current function.
- 20 August 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 522-525
Can MQ232 guide to novel options for treatment of ADPKD?
- 20 August 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 522-525
Can MQ232 guide to novel options for treatment of ADPKD?
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (31) , 14983-14992
Synthesis and characterization of cortinarins – cryptic cyclic peptides from mushrooms of the genus Cortinarius
First total synthesis of cortinarins A–C, cryptic cyclic peptides exhibiting non-classical atropisomerism. They mimic vasopressin-induced aquaporin-2 membrane localization through a distinct mode of action, offering leads for diabetes insipidus.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (31) , 14983-14992
Open AccessSynthesis and characterization of cortinarins – cryptic cyclic peptides from mushrooms of the genus Cortinarius
First total synthesis of cortinarins A–C, cryptic cyclic peptides exhibiting non-classical atropisomerism. They mimic vasopressin-induced aquaporin-2 membrane localization through a distinct mode of action, offering leads for diabetes insipidus.
- Open Access
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Live-cell quantitative monitoring reveals distinct, high-affinity Gβγ regulations of GIRK2 and GIRK1/2 channels
G i/o protein-coupled receptors (GPCRs) inhibit cardiac and neuronal excitability via G protein-activated K + channels (GIRK), assembled by combinations of GIRK1 - GIRK4 subunits. GIRKs are activated by direct binding of the Gβγ dimer of inhibitory G i/o proteins. However, key aspects of this textbook signaling pathway remain debated. Recent studies suggested no G i/o -GIRK pre-coupling and low (>250 µM) Gβγ-GIRK interaction affinity, contradicting earlier sub-µM estimates and implying low signaling efficiency. We show that Gγ prenylation, which mediates Gβγ membrane attachment required for GIRK activation, also contributes to the Gβγ-GIRK interaction, explaining the poor affinity obtained with non-prenylated Gβγ. Using quantitative protein titration and electrophysiology in live Xenopus oocytes, Gβγ affinity for homotetrameric GIRK2 ranges from 4-30 µM. Heterotetrameric GIRK1/2 shows a higher Gβγ apparent affinity due to the Gβγ-docking site (anchor) in GIRK1, which enriches Gβγ at the channel. Biochemical approaches and molecular dynamic simulations reveal that the Gβγ anchor is formed by interacting N-terminal and distal C-terminal domains of the GIRK1 subunits, distinct from the Gβγ-binding “activation” site(s) underlying channel opening. Thus, the affinity of Gβγ-GIRK interaction is within the expected physiological range, while dynamic pre-coupling of Gβγ to GIRK1-containing channels through high-affinity interactions further enhances the GPCR-G i/o -GIRK signaling efficiency.
- 24 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessLive-cell quantitative monitoring reveals distinct, high-affinity Gβγ regulations of GIRK2 and GIRK1/2 channels
G i/o protein-coupled receptors (GPCRs) inhibit cardiac and neuronal excitability via G protein-activated K + channels (GIRK), assembled by combinations of GIRK1 - GIRK4 subunits. GIRKs are activated by direct binding of the Gβγ dimer of inhibitory G i/o proteins. However, key aspects of this textbook signaling pathway remain debated. Recent studies suggested no G i/o -GIRK pre-coupling and low (>250 µM) Gβγ-GIRK interaction affinity, contradicting earlier sub-µM estimates and implying low signaling efficiency. We show that Gγ prenylation, which mediates Gβγ membrane attachment required for GIRK activation, also contributes to the Gβγ-GIRK interaction, explaining the poor affinity obtained with non-prenylated Gβγ. Using quantitative protein titration and electrophysiology in live Xenopus oocytes, Gβγ affinity for homotetrameric GIRK2 ranges from 4-30 µM. Heterotetrameric GIRK1/2 shows a higher Gβγ apparent affinity due to the Gβγ-docking site (anchor) in GIRK1, which enriches Gβγ at the channel. Biochemical approaches and molecular dynamic simulations reveal that the Gβγ anchor is formed by interacting N-terminal and distal C-terminal domains of the GIRK1 subunits, distinct from the Gβγ-binding “activation” site(s) underlying channel opening. Thus, the affinity of Gβγ-GIRK interaction is within the expected physiological range, while dynamic pre-coupling of Gβγ to GIRK1-containing channels through high-affinity interactions further enhances the GPCR-G i/o -GIRK signaling efficiency.
- Open Access
PDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling
Phosphodiesterase 3A (PDE3A) hydrolyses cAMP, adjusting cAMP signalling pathways with temporal and spatial accuracy. PDE3A contributes to the control of cAMP in several cellular compartments, including the plasma membrane, the cytosol, or membrane-limited organelles such as the nucleus and the sarcoplasmic reticulum. Through this ability and its expression in various cell types, it regulates a variety of cellular processes like contractility of muscle cells, gene expression, differentiation and proliferation. Dysregulated cAMP signalling causes or is associated with diseases. The therapeutic potential of PDE3A is, however, limited by the lack of specific modulators. Emerging approaches to targeting PDE3A centre on specifically addressing its catalytic domain or its cellular localisation. This review highlights the growing knowledge of PDE3A’s functions in cellular signalling and therapeutic opportunities, opening the door to more fully utilise its potential for the treatment of disease.
Open AccessPDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling
Phosphodiesterase 3A (PDE3A) hydrolyses cAMP, adjusting cAMP signalling pathways with temporal and spatial accuracy. PDE3A contributes to the control of cAMP in several cellular compartments, including the plasma membrane, the cytosol, or membrane-limited organelles such as the nucleus and the sarcoplasmic reticulum. Through this ability and its expression in various cell types, it regulates a variety of cellular processes like contractility of muscle cells, gene expression, differentiation and proliferation. Dysregulated cAMP signalling causes or is associated with diseases. The therapeutic potential of PDE3A is, however, limited by the lack of specific modulators. Emerging approaches to targeting PDE3A centre on specifically addressing its catalytic domain or its cellular localisation. This review highlights the growing knowledge of PDE3A’s functions in cellular signalling and therapeutic opportunities, opening the door to more fully utilise its potential for the treatment of disease.
- Open Access
Tripartite interactions of PKA catalytic subunit and C-terminal domains of cardiac Ca 2+ channel modulate its β-adrenergic regulation
The adrenergic nervous system augments cardiac contraction by increasing the activity of L-type voltage-gated Ca V 1.2 channels. Dysregulation of this process is linked to severe cardiac dysfunctions. The signaling cascade involves activation of β-adrenergic receptors, elevation of cAMP levels, separation of protein kinase A (PKA) regulatory subunit (PKAR) from catalytic subunit (PKAC), and phosphorylation of the inhibitory protein Rad leading to increased Ca 2+ influx. In cardiomyocytes, the core subunit of Ca V 1.2 (α 1C ) exists in two forms: full-length (FL) or proteolytically processed (truncated), lacking the distal C-terminus (dCT). Specificity and efficiency in the cascade are believed to emanate from unique protein-protein interactions, such as anchoring PKA (via PKAR) to α 1C by A-kinase anchoring proteins (AKAPs). However, most AKAPs do not interact with the truncated α 1C , and their role in βAR regulation of cardiac Ca V 1.2 remains unclear. Here we show that PKAC, independently of PKAR or AKAPs, directly interacts with α 1C at two domains in α 1C -CT: the proximal and distal C-terminal regulatory domains (PCRD and DCRD), which also interact with each other. Furthermore, we find that DCRD competes with PCRD and reduces its interaction with PKAC. The physiological consequences of these complex interactions are incompletely understood; our data suggest that they may fine-tune the βAR regulation of Ca V 1.2. We propose that the newly discovered interactions take part in governing colocalization of regulatory proteins within the βAR-Ca V 1.2 multimolecular signaling complexes in cardiomyocytes.
Open AccessTripartite interactions of PKA catalytic subunit and C-terminal domains of cardiac Ca 2+ channel modulate its β-adrenergic regulation
The adrenergic nervous system augments cardiac contraction by increasing the activity of L-type voltage-gated Ca V 1.2 channels. Dysregulation of this process is linked to severe cardiac dysfunctions. The signaling cascade involves activation of β-adrenergic receptors, elevation of cAMP levels, separation of protein kinase A (PKA) regulatory subunit (PKAR) from catalytic subunit (PKAC), and phosphorylation of the inhibitory protein Rad leading to increased Ca 2+ influx. In cardiomyocytes, the core subunit of Ca V 1.2 (α 1C ) exists in two forms: full-length (FL) or proteolytically processed (truncated), lacking the distal C-terminus (dCT). Specificity and efficiency in the cascade are believed to emanate from unique protein-protein interactions, such as anchoring PKA (via PKAR) to α 1C by A-kinase anchoring proteins (AKAPs). However, most AKAPs do not interact with the truncated α 1C , and their role in βAR regulation of cardiac Ca V 1.2 remains unclear. Here we show that PKAC, independently of PKAR or AKAPs, directly interacts with α 1C at two domains in α 1C -CT: the proximal and distal C-terminal regulatory domains (PCRD and DCRD), which also interact with each other. Furthermore, we find that DCRD competes with PCRD and reduces its interaction with PKAC. The physiological consequences of these complex interactions are incompletely understood; our data suggest that they may fine-tune the βAR regulation of Ca V 1.2. We propose that the newly discovered interactions take part in governing colocalization of regulatory proteins within the βAR-Ca V 1.2 multimolecular signaling complexes in cardiomyocytes.
- Open Access
- 13 July 2023
- Published by Wiley in The Journal of Physiology
- Vol. 602 (13) , 3025-3039
Many kinases for controlling the water channel aquaporin‐2
Aquaporin‐2 (AQP2) is a member of the aquaporin water channel family. In the kidney, AQP2 is expressed in collecting duct principal cells where it facilitates water reabsorption in response to antidiuretic hormone (arginine vasopressin, AVP). AVP induces the redistribution of AQP2 from intracellular vesicles and its incorporation into the plasma membrane. The plasma membrane insertion of AQP2 represents the crucial step in AVP‐mediated water reabsorption. Dysregulation of the system preventing the AQP2 plasma membrane insertion causes diabetes insipidus (DI), a disease characterised by an impaired urine concentrating ability and polydipsia. There is no satisfactory treatment of DI available. This review discusses kinases that control the localisation of AQP2 and points out potential kinase‐directed targets for the treatment of DI. image
- 13 July 2023
- Published by Wiley in The Journal of Physiology
- Vol. 602 (13) , 3025-3039
Open AccessMany kinases for controlling the water channel aquaporin‐2
Aquaporin‐2 (AQP2) is a member of the aquaporin water channel family. In the kidney, AQP2 is expressed in collecting duct principal cells where it facilitates water reabsorption in response to antidiuretic hormone (arginine vasopressin, AVP). AVP induces the redistribution of AQP2 from intracellular vesicles and its incorporation into the plasma membrane. The plasma membrane insertion of AQP2 represents the crucial step in AVP‐mediated water reabsorption. Dysregulation of the system preventing the AQP2 plasma membrane insertion causes diabetes insipidus (DI), a disease characterised by an impaired urine concentrating ability and polydipsia. There is no satisfactory treatment of DI available. This review discusses kinases that control the localisation of AQP2 and points out potential kinase‐directed targets for the treatment of DI. image
- 13 July 2023
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 71, 102392
Targeting cAMP signaling compartments in iPSC-derived models of cardiovascular disease
- 13 July 2023
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 71, 102392
Targeting cAMP signaling compartments in iPSC-derived models of cardiovascular disease